Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG CLASS:
DNA synthesis inhibitor
DRUG CLASS:
DNA synthesis inhibitor
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Related drugs:
‹
cisplatin (306)
gemcitabine (151)
temozolomide (104)
cytarabine (95)
oxaliplatin (51)
dacarbazine (22)
cytarabine/daunorubicin liposomal formulation (19)
clofarabine (16)
carmustine (14)
temozolomide gel (7)
mitomycin (7)
nedaplatin (5)
nelarabine (5)
streptozocin (5)
fludarabine IV (4)
bleomycin (3)
hydroxyurea (3)
mercaptopurine (3)
thiotepa (3)
fotemustine (2)
thioguanine (2)
fosgemcitabine palabenamide (1)
asparagine cytarabine conjugate (1)
mitomycin urothelial gel (1)
fludarabine oral (1)
cisplatin (306)
gemcitabine (151)
temozolomide (104)
cytarabine (95)
oxaliplatin (51)
dacarbazine (22)
cytarabine/daunorubicin liposomal formulation (19)
clofarabine (16)
carmustine (14)
temozolomide gel (7)
mitomycin (7)
nedaplatin (5)
nelarabine (5)
streptozocin (5)
fludarabine IV (4)
bleomycin (3)
hydroxyurea (3)
mercaptopurine (3)
thiotepa (3)
fotemustine (2)
thioguanine (2)
fosgemcitabine palabenamide (1)
asparagine cytarabine conjugate (1)
mitomycin urothelial gel (1)
fludarabine oral (1)
›
Associations
(785)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
MGMT unmethylation
Glioma
MGMT unmethylation
Glioma
temozolomide + interferon α-2b
Sensitive: B - Late Trials
JAMA Netw Open - 1 week (New B)
temozolomide + interferon α-2b
Sensitive
:
B
JAMA Netw Open - 1wk
temozolomide + interferon α-2b
Sensitive: B - Late Trials
JAMA Netw Open - 1 week
temozolomide + interferon α-2b
Sensitive
:
B
JAMA Netw Open - 1 week - (New B)
KRAS G12R
Pancreatic Ductal Adenocarcinoma
KRAS G12R
Pancreatic Ductal Adenocarcinoma
paclitaxel + gemcitabine
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
paclitaxel + gemcitabine
Sensitive
:
C3
ASCO-GI 2023 - 2wk
paclitaxel + gemcitabine
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
paclitaxel + gemcitabine
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
No biomarker
Squamous Cell Carcinoma of Head and Neck
No biomarker
Squamous Cell Carcinoma of Head and Neck
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
No biomarker
Gastric Adenocarcinoma
No biomarker
Gastric Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
No biomarker
Gastroesophageal Junction Adenocarcinoma
No biomarker
Gastroesophageal Junction Adenocarcinoma
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A1 - Approval
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A1
No biomarker
Non Small Cell Lung Cancer
No biomarker
Non Small Cell Lung Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
No biomarker
Acute Myelogenous Leukemia
No biomarker
Acute Myelogenous Leukemia
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
cytarabine/daunorubicin liposomal formulation
Sensitive: A1 - Approval
cytarabine / daunorubicin liposomal formulation
Sensitive
:
A1
No biomarker
Testicular Cancer
No biomarker
Testicular Cancer
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
No biomarker
Astrocytoma
No biomarker
Astrocytoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Ependymoma
No biomarker
Ependymoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Medulloblastoma
No biomarker
Medulloblastoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Anaplastic Astrocytoma
No biomarker
Anaplastic Astrocytoma
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
No biomarker
Hodgkin Lymphoma
No biomarker
Hodgkin Lymphoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Non-Hodgkin’s Lymphoma
No biomarker
Non-Hodgkin’s Lymphoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Urothelial Cancer
No biomarker
Urothelial Cancer
mitomycin urothelial gel
Sensitive: A1 - Approval
mitomycin urothelial gel
Sensitive
:
A1
mitomycin urothelial gel
Sensitive: A1 - Approval
mitomycin urothelial gel
Sensitive
:
A1
No biomarker
Malignant Pleural Mesothelioma
No biomarker
Malignant Pleural Mesothelioma
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
No biomarker
Lung Non-Squamous Non-Small Cell Cancer
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
cisplatin + pemetrexed
Sensitive: A1 - Approval
cisplatin + pemetrexed
Sensitive
:
A1
No biomarker
Pancreatic Adenocarcinoma
No biomarker
Pancreatic Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A1
gemcitabine + albumin-bound paclitaxel
Sensitive: A1 - Approval
gemcitabine + albumin-bound paclitaxel
Sensitive
:
A1
No biomarker
T Cell Non-Hodgkin Lymphoma
No biomarker
T Cell Non-Hodgkin Lymphoma
nelarabine
Sensitive: A1 - Approval
nelarabine
Sensitive
:
A1
nelarabine
Sensitive: A1 - Approval
nelarabine
Sensitive
:
A1
No biomarker
T Acute Lymphoblastic Leukemia
No biomarker
T Acute Lymphoblastic Leukemia
nelarabine
Sensitive: A1 - Approval
nelarabine
Sensitive
:
A1
nelarabine
Sensitive: A1 - Approval
nelarabine
Sensitive
:
A1
No biomarker
Acute Lymphocytic Leukemia
No biomarker
Acute Lymphocytic Leukemia
mercaptopurine
Sensitive: A1 - Approval
mercaptopurine
Sensitive
:
A1
mercaptopurine
Sensitive: A1 - Approval
mercaptopurine
Sensitive
:
A1
No biomarker
Bladder Cancer
No biomarker
Bladder Cancer
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
cisplatin
Sensitive: A1 - Approval
cisplatin
Sensitive
:
A1
No biomarker
Glioma
No biomarker
Glioma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
temozolomide
Sensitive: A1 - Approval
temozolomide
Sensitive
:
A1
No biomarker
Glioblastoma
No biomarker
Glioblastoma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Multiple Myeloma
No biomarker
Multiple Myeloma
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
carmustine
Sensitive: A1 - Approval
carmustine
Sensitive
:
A1
No biomarker
Thyroid Gland Medullary Carcinoma
No biomarker
Thyroid Gland Medullary Carcinoma
dacarbazine
Sensitive: A2 - Guideline
dacarbazine
Sensitive
:
A2
dacarbazine
Sensitive: A2 - Guideline
dacarbazine
Sensitive
:
A2
No biomarker
Small Intestinal Carcinoma
No biomarker
Small Intestinal Carcinoma
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
gemcitabine + docetaxel
Sensitive: A2 - Guideline
gemcitabine + docetaxel
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + paclitaxel + 5-fluorouracil
Sensitive
:
A2
cisplatin + paclitaxel + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + paclitaxel + 5-fluorouracil
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin + docetaxel
Sensitive: A2 - Guideline
cisplatin + docetaxel
Sensitive
:
A2
cisplatin + docetaxel
Sensitive: A2 - Guideline
cisplatin + docetaxel
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
cisplatin
Sensitive: A2 - Guideline
cisplatin
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A2
cisplatin + docetaxel + 5-fluorouracil
Sensitive: A2 - Guideline
cisplatin + docetaxel + 5-fluorouracil
Sensitive
:
A2
No biomarker
Oral Cancer
No biomarker
Oral Cancer
cisplatin + paclitaxel
Sensitive: A2 - Guideline
cisplatin + paclitaxel
Sensitive
:
A2
cisplatin + paclitaxel
Sensitive: A2 - Guideline
cisplatin + paclitaxel
Sensitive
:
A2
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login